ERR

ERR

Estrogen receptors are a group of proteins found inside cells.They are receptors that the estrogen (17-estradiol) hormone activates. There are two classes of estrogen receptors: GPER (GPR30), a member of the rhodopsin-like family of G protein-coupled receptors, and ER, a member of the nuclear hormone family of intracellular receptors. The interactions between coactivators and corepressors, and consequently, the agonist or antagonist effect of the ligand, are heavily influenced by the ER's helix 12 domain.Different ligands may have different affinities for the estrogen receptor's alpha and beta isoforms. Estradiol binds to both receptors equally well, however raloxifene, estrone, and genistein bind preferentially to the alpha receptor. In addition to being necessary for sexual maturation and reproductive function, estrogen and its receptors also affect other tissues, like bone. In pathological conditions like osteoporosis, endometrial cancer, and breast cancer, estrogen receptors play a role. Numerous transcript variations are produced by alternative promoter use and alternative splicing, however it is unknown how many of these variants are full-length.

ERR related products

Structure Cat No. Product Name CAS No. Product Description
V67665 GNE-502 1953134-16-1 GNE-502 is an orally bioavailable estrogen receptor (ER) degrader.
V67648 GPR30 agonist-1 415919-74-3 GPR30 agonist-1 is a G protein-coupled receptor 30 (GPR30) agonist.
V3533 GSK-4716 101574-65-6 GSK4716 is a novel, potent and selective estrogen-related receptor beta/gamma (ERRβ and ERRγ) agonist.
V21885 GSK5182 877387-37-6 GSK5182 is a novel, potent, highly specific and orally bioactive inverse agonist of estrogen-related receptor γ (ERRγ) with an IC50 of 79 nM.
V67651 GW7604 361203-06-7 GW7604 is an antiestrogen.
V67650 Imlunestrant (LY-3484356) 2408840-26-4 Imlunestrant (LY-3484356) is an orally bioactive and selective estrogen receptor degrader (SERD) with purely antagonistic properties.
V67652 Imlunestrant tosylate (LY-3484356 tosylate) 2408840-41-3 Imlunestrant (LY-3484356) tosylate is an orally bioactive and selective estrogen receptor degrader (SERD) with purely antagonistic properties.
V67706 Inokosterone 15130-85-5 Inokosterone is a potentially active molecular target of estrogen receptor 1 in patients with rheumatoid arthritis.
V1994 Kaempferol (Kempferol; Robigenin) 520-18-3 Kaempferol (Kempferol; Robigenin), a naturally occuring flavonoid analog, is a potent ERRα (estrogen receptor α) and ERRγ inverse agonist.
V3805 LSZ102 2135600-76-7 LSZ-102 is a potent, orally bioactive and selective ERα antagonist and SERD (estrogen receptordegrader) with anIC50of 0.2 nM has the potentialfor the treatment of Estrogen Receptor Positive Breast Cancer.
V67693 Millewanin G 874303-33-0 Millewanin G is a prenylated isoflavonoid compound with antiestrogenic activity (IC50=29 μM).
V67715 OP-1074 1443752-76-8 OP-1074, a pure anti-estrogen, is a selective ER degrader (PA-SERD) with specific anti-estrogenic activity on ERα and ERβ, inhibiting 17β-estradiol (E2)-stimulated transcriptional activity, IC50 are 1.6 and 3.2 nM respectively.
V67657 Palazestrant (OP-1250) 2092925-89-6 Palazestrant is an antiestrogenic and anticancer agent.
V3204 PHTPP 805239-56-9 PHTPP is an antagonist of the ERβ (Estrogen Receptor).
V67643 Psidial A 1207181-35-8 Psidial A is an epimer of the sesquiterpene-diphenylmethane terpenoid.
V67698 Raloxifene-d10-1 (Keoxifene-d10; LY156758(free base)-d10; LY139481-d10) 2512224-37-0 Raloxifene-d10-1 is the deuterated form of Raloxifene.
V67697 Raloxifene-d4 1185076-44-1 Raloxifene-d4 is the deuterated form of Raloxifene.
V67707 Raloxifene-d4 hydrochloride 1188263-47-9 Raloxifene-d4 ( HCl) is the deuterated form of Raloxifene.
V60133 SLU-PP-1072 2285432-57-5 SLU-PP-1072 is a dual ERRα/γ inverse agonis,induces apoptosis via dysregulating cell cycle.It disrupts PCa cell metabolism and can be used in Prostate cancer (PCa) research.
V67664 SNIPER(ER)-110 2241690-03-7 SNIPER(ER)-110 consists of IAP ligand and estrogen ligand, connected through a linker.
Contact Us Back to top